---
document_datetime: 2024-09-05 13:21:29
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/betmiga-epar-all-authorised-presentations_en.pdf
document_name: betmiga-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 2.2352835
conversion_datetime: 2025-12-24 21:19:53.884472
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
| MA (EU) number   | (Invented) name   | Strength   | Pharmaceutical Form                            | Route of Administration   | Immediate Packaging   | Content (concentration)   | Pack size                                               |
|------------------|-------------------|------------|------------------------------------------------|---------------------------|-----------------------|---------------------------|---------------------------------------------------------|
| EU/1/12/809/001  | Betmiga           | 25 mg      | Prolonged-release tablet                       | Oral use                  | blister (alu/alu)     |                           | 10 tablets                                              |
| EU/1/12/809/002  | Betmiga           | 25 mg      | Prolonged-release tablet                       | Oral use                  | blister (alu/alu)     |                           | 20 tablets                                              |
| EU/1/12/809/003  | Betmiga           | 25 mg      | Prolonged-release tablet                       | Oral use                  | blister (alu/alu)     |                           | 30 tablets                                              |
| EU/1/12/809/004  | Betmiga           | 25 mg      | Prolonged-release tablet                       | Oral use                  | blister (alu/alu)     |                           | 60 tablets                                              |
| EU/1/12/809/005  | Betmiga           | 25 mg      | Prolonged-release tablet                       | Oral use                  | blister (alu/alu)     |                           | 90 tablets                                              |
| EU/1/12/809/006  | Betmiga           | 25 mg      | Prolonged-release tablet                       | Oral use                  | blister (alu/alu)     |                           | 200 tablets                                             |
| EU/1/12/809/008  | Betmiga           | 50 mg      | Prolonged-release tablet                       | Oral use                  | blister (alu/alu)     |                           | 10 tablets                                              |
| EU/1/12/809/009  | Betmiga           | 50 mg      | Prolonged-release tablet                       | Oral use                  | blister (alu/alu)     |                           | 20 tablets                                              |
| EU/1/12/809/010  | Betmiga           | 50 mg      | Prolonged-release tablet                       | Oral use                  | blister (alu/alu)     |                           | 30 tablets                                              |
| EU/1/12/809/011  | Betmiga           | 50 mg      | Prolonged-release tablet                       | Oral use                  | blister (alu/alu)     |                           | 60 tablets                                              |
| EU/1/12/809/012  | Betmiga           | 50 mg      | Prolonged-release tablet                       | Oral use                  | blister (alu/alu)     |                           | 90 tablets                                              |
| EU/1/12/809/013  | Betmiga           | 50 mg      | Prolonged-release tablet                       | Oral use                  | blister (alu/alu)     |                           | 200 tablets                                             |
| EU/1/12/809/015  | Betmiga           | 25 mg      | Prolonged-release tablet                       | Oral use                  | blister (alu/alu)     |                           | 50 tablets                                              |
| EU/1/12/809/016  | Betmiga           | 25 mg      | Prolonged-release tablet                       | Oral use                  | blister (alu/alu)     |                           | 100 tablets                                             |
| EU/1/12/809/017  | Betmiga           | 50 mg      | Prolonged-release tablet                       | Oral use                  | blister (alu/alu)     |                           | 50 tablets                                              |
| EU/1/12/809/018  | Betmiga           | 50 mg      | Prolonged-release tablet                       | Oral use                  | blister (alu/alu)     |                           | 100 tablets                                             |
| EU/1/12/809/019  | Betmiga           | 8 mg/ml    | Granules for prolonged-release oral suspension | Oral use                  | bottle (PET)          | 830 mg                    | 1 bottle + 1 measuring cup 1 syringe + 1 bottle adaptor |
| EU/1/12/809/020  | Betmiga           | 8 mg/ml    | Granules for prolonged-release oral suspension | Oral use                  | bottle (PET)          | 830 mg                    | 1 bottle + 1 syringe + 1 bottle adaptor                 |